Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges

lt;p>Myron Christodoulides is Professor of Bacteriology in the School of Clinical and Experimental Sciences, in the Faculty of Medicine, University of Southampton. He is a graduate in microbiology from University College London and the University of Glasgow, and his interests are broad, encompassing the development of vaccines for bacterial infections and for neglected tropical diseases of humans and animals; drug discovery for novel antimicrobials; development of rapid diagnostic assays; understanding the pathogenesis mechanisms of bacterial infections. Central to his research is multi- and inter-disciplinary collaboration with colleagues all over the world. He has edited previously the books Neisseria meningitidis: Advanced Methods and Protocols (2011) and Neisseria gonorrhoeae: Methods and Protocols (2019) for Springer and Meningitis: Cellular and Molecular Basis (2013) for CABI. He is the author of ~120 research articles and reviews in vaccinology and microbial pathogenesis and has contributed a dozen or more chapters to published books. He is currently Specialty Chief Editor of the Pathogenesis, Vaccines, and Immunity of Bacterial Infections specialty section of Frontiers in Bacteriology and sits on other journal editorial boards. He has recently published in Leishmania diagnostics and vaccine development.

Preface by Prof Myron Christodoulides, University of Southampton, UK.-1. Introduction chapter on the VALIDATE network.- (Prof Helen McShane, Director Oxford NIHR Biomedical Research Centre, University of Oxford, UK and Samantha Vermaak, The Jenner Institute Laboratories, Oxford, UK).- Part I: Leprosy.- 2. Leprosy challenges to vaccine developers.- (Dr Hua Wang, University of Glasgow, UK).- 3. Leprosy vaccine development.- (Dr Khushboo Borah, University of Surrey, UK).- Part II: Tuberculosis.- 4. Biomarkers in tuberculosis vaccine development.- (Dr Kenneth Akwue, University of the Witwatersrand, Johannesburg, South Africa).- 5. Tuberculosis correlates of protection (Dr Rachel Tanner, The Jenner Institute Laboratories, Oxford, UK),.- Animal models for tuberculosis(Dr. Hao Li, China Agricultural University, Beijing, China).- 7. BCG vaccination .- (Dr Hazel Morrison, The Jenner Institute Laboratories, Oxford, UK).- 8. Vaccination strategies for Buruli ulcer disease (Dr  Rachel Simmonds, University of Surrey, UK).- 9. Fermentation in vaccine development (BCG)(Dr. Joanna Bacon, Public Health England, UK Government, London, UK).- Part III: Leishmaniasis:10. Human leishmaniasis vaccination.- (Dr Ali Bordbar, Institute Pasteur of Iran, Tehran, Iran).- 11. Aspects of human leishmaniasis vaccine use.- (Dr  Olayinka Osuolale, Elizade University, Ilara-Mokin, Nigeria).- 12. Human challenge model for developing leishmaniasis vaccines (Prof Paul Kaye, University of York, UK).- 13. Canine leishmaniasis vaccines.- (Prof Eduardo Coelho, Federal University of Minas Gerais, Belo Horizonte, Brazil and Prof Myron Christodoulides, University of Southampton, UK).- Part IV: Melioidosis.- 14. Vaccines for melioidosis (Prof Chiranjay Mukhopadhyay, Kasturba Medical College, Manipal, India).- 15. West Africa burden of disease (Dr Tukur Ismail, Zamfara State Primary Healthcare Board, Gusau, Nigeria)